host manag meet ghdx ceo cfo vice-president ir came away
posit ghdx near- long-term outlook base commentari surround
tailorx recept us abroad ivd develop prostat
reimburs said believ growth driver larg captur
current valuat increas price target
genom health manag expect recent tailorx data increas overal
adopt invas breast gene express test current elig patient
us use test annual increas ghdx share posit competitor
includ agendia
drive adopt higher compani invest educ program inform
dabbler provid order test infrequ tailorx data
benefit order oncotyp
accord ghdx dabbler characterist order test infrequ
main reason provid gotten comfort make treatment decis
certain patient popul cm tumor size therefor see util
predict test patient provid would avoid order oncotyp
prefer convers patient intermedi result
data inconclus and/or provid would order compet molecular profil
test instead oncotyp
tailorx seemingli address issu studi demonstr
provid guess patient recurr score doctor would over-treat
would under-treat base clinic factor alon show provid would over-
treat patient compet test use remov intermedi categori
recurr score make treatment recommend much clearer
manag indic tailorx data start reson among provid
particularli dabbler us compani note strong order
momentum saw june follow tailorx data releas continu
believ encourag consid compani still fulli educ provid
tailorx data
addit tailorx data educ program guidelin revis could also
tailwind drive provid order although oncotyp current major guidelin
today ghdx expect us guidelin updat soon wake tailorx data
even support test includ rel test ultim
compani believ develop relat guidelin could occur end year
possibl and/or nccn thing mind compani believ
take month oncotyp breast reach market penetr us
believ us remain key revenu growth driver ghdx next
continu page
pleas see page report import disclosur
genom health uniqu clinic research regulatori reimburs expertis
one establish leader cancer-focus advanc genet genom
diagnost market fulli believ promis advanc genom genet
diagnost expect genom remain lead develop provid
complex genet diagnost servic year come subsequ year stock
under-perform believ combin acceler revenu increas
confid pipeline/ second act potenti oper break-even posit
ghdx revenu multipl upsid
prostat reimburs coverag
colon penetr acceler
absenc chemotherapi benefit label
bit limit
prostat provid meaning sourc
revenu next sever year
privat payer expand
coverag expand prostat revenu
ou growth continu acceler
materi growth breast
indic colon fail materi
genom health focus develop commerci clinic laboratori
test servic aim help physician patient make individu cancer
genom analysi tumor biopsi specimen provid tumor-specif inform genom
launch first test oncotyp dx breast cancer aid predict
likelihood cancer recurr likelihood chemotherapi benefit earli stage
breast cancer patient beyond breast cancer oncotyp dx colon cancer launch
oncotyp dx prostat cancer launch may
although oncotyp breast penetr us penetr
key ou market today area test histor hamper
reimburs sampl restrict among factor howev reimburs
environ start improv follow tailorx data
exampl german assess bodi iqwig issu favor decis last week
specif oncotyp dx breast decis use guid countri
public insur g-ba anticip make coverag decis end year
reimburs price yet establish said believ argument
made g-ba reimburs rate even would posit
develop ghdx although would step current list price
believ would posit develop consid ghdx would
reimburs far often test today volum would like increas
due broader access actual timelin price consist expect
countri would repres patient annual opportun manag
indic expect test reimburs level volum margin
ghdx continu expect reimburs updat region includ uk
updat renew decis expect next month franc
nation reimburs updat expect compani note also
make progress japan
oncotyp breast ivd biocarti product track late launch ivd
ghdx ostens cusp make major inroad breast cancer
test intern mani countri requir test run within border block
shipment sampl ghdx california lab would therefor necessit ghdx
establish lab within countri launch decentr ivd solut addit
mani instanc prefer sampl assay hous
compani made quicker expect progress latter base
biocarti idylla platform idylla consul cost instal base
instrument eu total instal base expect approxim
instrument year end ghdx indic chose platform other
best posit perform amount multiplex requir gene
test develop ivd idylla cartridg also compel day
turnaround time low expect cog compar oncotyp
run ghdx
ghdx anticip ivd launch oncotyp breast test late franc
germani expans market afterward potenti futur market includ
china biocarti make inroad us biocarti alreadi
success take test fda ghdx also discuss develop ivd
product outsid oncotyp breast includ oncotyp prostat ghdx
believ could attract us sinc mani urologist valu test perform
lab compani believ bladder renal pipelin product could good
ivd candid well
guidelin chang payer demonstr studi could catalyz adopt oncotyp
activ surveil prostat cancer increas patient
past year believ driven least part adopt
stratifi prostat profil test genom health genomedx
penetr market today remind medicar current
reimburs use oncotyp prostat low intermedi risk prostat cancer
patient privat payer reimburs rate slightli higher ghdx
contract live time commerci cover live
rate privat payer adopt lag intern expect manag believ
recent guidelin chang on-going observ payer demonstr studi
help address payer hesit develop seem effect
alreadi top commerci payer believ recent announc
posit coverag decis ghdx test
recent hire sale rep ghdx urolog sale forc seem well-built drive
volum us sale forc rep believ plenti
consid concentr urologist
ghdx also provid updat timelin reimburs rate commerci
plan oncotyp dx nucleu detect test develop epic
scienc liquid biopsy-bas test identifi prostat cancer patient
longer benefit androgen receptor signal inhibitor arsi therapi
remind issu favor draft local coverag decis march
ghdx expect favor final reimburs decis come
day week compani expect reimburs rate consid
cours androgen receptor ar treatment per month seem like
product would compel valu proposit expect rate
men metastat resist prostat cancer could benefit test
would cms-elig popul indic market opportun
cms-elig popul per agreement ghdx epic would split
would like contribut ghdx revenu decis happen
near futur although compani includ modest contribut
product revenu guidanc ghdx plan leverag rep
oncolog channel peopl urolog channel sell product
although ghdx seem plenti focu current disclos
opportun compani enthus potenti futur direct compani
could licens test epic scienc pipelin potenti integr epic
ghdx busi partner close biocarti sell exist
biocarti product ghdx commerci channel addit ghdx discuss
possibl could move earlier stage diseas addit genom
could develop addit oncotyp product global biocarti platform
mention earlier prostat bladder renal ghdx share valu increas
materi last sever month cash flow gener improv believ
compani could well posit futur act opportun would
leverag uniqu commerci channel
compar compani lh trade averag
ev/sal median sale estim ghdx would valu
like bia given bia upsid rel current sale
attract stori clearli improv said believ like larg
captur valuat current level
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit reimburs cut test price delay weaker-
than-expect clinic data support new product competit result market
share eros weaker-than-expect uptak intern market deliv
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock genom health thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc septemb et dissemin septemb et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
